Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/17/2025

Treatment Recommendations for Mycoplasma Hominis and Ureaplasma Parvum Detection

Introduction to Treatment Guidelines

  • The Centers for Disease Control and Prevention recommends that patients with positive test results for Mycoplasma hominis and Ureaplasma parvum should not be treated based solely on these results 1, 2

Clinical Assessment and Diagnostic Criteria

  • The American College of Physicians suggests determining if objective urethritis is present by documenting any of the following: mucopurulent or purulent urethral discharge on examination, Gram stain showing ≥5 WBCs per oil immersion field, positive leukocyte esterase test on first-void urine, or microscopic examination of first-void urine showing ≥10 WBCs per high-power field 3, 4, 2
  • The Infectious Diseases Society of America recommends excluding true STI pathogens, including Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium, before attributing symptoms to Mycoplasma hominis or Ureaplasma species 1, 4

Treatment Algorithm and Regimens

  • The European Society of Clinical Microbiology and Infectious Diseases suggests treating only if all of the following are true: objective urethritis is documented, N. gonorrhoeae, C. trachomatis, M. genitalium, and T. vaginalis are excluded, the detected organism is U. urealyticum with high load on quantitative testing, and symptoms persist despite appropriate evaluation 1, 2, 4
  • The American College of Physicians recommends doxycycline 100 mg orally twice daily for 7 days as the first-line treatment, with an alternative regimen of azithromycin 1 g orally as a single dose, and an additional alternative of erythromycin base 500 mg orally four times daily for 7 days 1, 2, 4

Partner Management and Follow-Up

  • The Centers for Disease Control and Prevention recommends that all sexual partners with contact within 60 days must be evaluated and treated if the index patient is treated, and that both patient and partners must abstain from sexual intercourse for 7 days after single-dose therapy or until completion of the 7-day regimen 1, 2
  • The Infectious Diseases Society of America suggests that test-of-cure is not routinely recommended after treatment unless symptoms persist or reinfection is suspected, and that patients should return for evaluation only if symptoms persist or recur after completing therapy 1, 2, 4

REFERENCES

1

Ureaplasma Infection Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2

Management of Detected Ureaplasma parvum and Ureaplasma urealyticum [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026